-
Jefferies Increases Sales Guidance on Cubist Pharmaceuticals
Friday, July 15, 2011 - 9:44am | 114Jefferies published a report on Cubist Pharmaceuticals (NASDAQ: CBST) that increased fiscal year guidance. In the research report, Jefferies wrote, "In 2Q11, U.S. Cubicin sales of $169M (~10% q/q) came in above our/cons estimates of $162M/$165M, respectively; slightly lower ex-U.S. Cubicin revenue...
-
Mitchel Sayare, Ph.D. to Succeed John Pappajohn as Chairman of the Company's Board of Directors
Friday, July 15, 2011 - 9:30am | 143PharmAthene, Inc. (NYSE: PIP) today announced that the Company's Board of Directors has elected Mitchel Sayare, Ph.D. to succeed John Pappajohn as Chairman of the Board. Mr. Pappajohn stepped down from the PharmAthene Board effective immediately. Dr. Sayare has been a member of PharmAthene's Board...
-
Karen A. Dawes Elected as Repligen Co-chairperson of the Board of Directors
Friday, July 15, 2011 - 9:20am | 137Repligen Corporation (NASDAQ: RGEN) announced today that Ms. Karen A. Dawes has been elected to serve as co-chairperson of the Board of Directors along with Mr. Alexander Rich, M.D. Ms. Dawes has served as a Director of Repligen since September of 2005 and has extensive experience in the...
-
UPDATE: Jefferies Raises PT on Seattle Genetics to $25
Friday, July 15, 2011 - 8:58am | 84Jefferies is out with its report today on Seattle Genetics (NASDAQ: SGEN), raising its PT from $22 to $25. In a note to clients, Jefferies writes, "We are raising our sum-of-parts PT from $22 ($15 Adcetris+ $3 collaborations+ $4 cash) to $25 ($18 Adcetris+ $3 collaborations+ $4 cash), based on a...
-
UPDATE: Oppenheimer Raising Its Price Target On Seattle Genetics (SGEN
Friday, July 15, 2011 - 8:50am | 176Oppenheimer & Co. is raising its price target on shares of Seattle Genetics (NASDAQ: SGEN) to $24 from $21, and it is keeping its Outperform rating on shares. In a note to clients, Oppenheimer & Co. writes, "On 7/14, an FDA Advisory Committee (AdCom) voted unanimously (10-0) in favor of...
-
Inovio Pharmaceuticals Demonstrates T Cell Immune Response Durability with Fourth Dose of Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
Friday, July 15, 2011 - 8:49am | 145Strong, persistent T cell responses observed up to over two years in 87% of assessed patients Inovio Pharmaceuticals, Inc. (NYSE: INO) has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients...
-
Bank of America Merrill Lynch Maintains Neutral on Cubist Pharmaceuticals
Friday, July 15, 2011 - 8:22am | 133Bank of America Merrill Lynch is out with its report today on Cubist Pharmaceuticals (NASDAQ: CBST), maintaining Neutral. In a note to clients, Bank of America Merrill Lynch writes, "We rate CBST shares Neutral and believe the stock is mostly fairly valued. A major overhang was recently lifted...
-
Oppenheimer Raises Price Target On Cubist Pharmaceuticals To $44
Friday, July 15, 2011 - 8:21am | 94According to Oppenheimer, Cubist Pharmaceuticals (NASDAQ: CBST) price target is raised to $44. Oppenheimer said that upon further analysis of the unique deal with TEVA regarding generic Cubicin's launch, and given the high degree of Cubicin manufacturing difficulty, it believes the Street is...
-
UPDATE: Oppenheimer Raises PT on Seattle Genetics to $24
Friday, July 15, 2011 - 7:37am | 114Oppenheimer is out with its report today on Seattle Genetics (NASDAQ: SGEN), raising its PT from $21 to $24. In a note to clients, Oppenheimer writes, "Our new 12- to 18-month price target for SGEN is $24 based on a ten-year DCF valuation with a free cash flow estimate of ~$200M in 2020 and a...
-
Jefferies Raises PT On Seattle Genetics To $25
Friday, July 15, 2011 - 7:19am | 27Jefferies & Company has raised the price target on Seattle Genetics (NASDAQ: SGEN) from $22 to $25 and maintains its Buy rating.
-
Amgen Announces XGEVA Granted Marketing Authorization in the European Union
Friday, July 15, 2011 - 7:03am | 100Amgen (NASDAQ: AMGN) today announced that the European Commission has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases...
-
Oppenheimer Raises PT On Cubist Pharmaceuticals To $44
Friday, July 15, 2011 - 6:40am | 26Oppenheimer has raised the price target on Cubist Pharmaceuticals (NASDAQ: CBST) from $37 to $44 and maintains its Outperform rating.
-
Oppenheimer Raises PT On Seattle Genetics To $24
Friday, July 15, 2011 - 6:10am | 26Oppenheimer has raised the price target on Seattle Genetics (NASDAQ: SGEN) from $21 to $24 and maintains its Outperform rating.
-
Innophos Holdings: Fairly Valued Unless Speculations Prove True ($IPHS)
Friday, July 15, 2011 - 6:00am | 1778Barron's magazine conducts an annual roundtable interview with seasoned money managers to gather insight into the markets and showcase some interesting investment opportunities. Midway through the year, Barron's publishes a follow-up to see how these managers' picks have performed and to see how...
-
ISI Provides Color on Biogen Idec
Friday, July 15, 2011 - 3:48am | 134ISI provided color on Biogen Idec (NASDAQ: BIIB). In a research report published today, ISI commented on the company's product Tysabri. In the report, ISI states, “Earlier today, BIIB released their July 2011 Tysabri update on the number of cases of PML for patients. Interestingly, they noted that...